Marta Díaz 1,2 , Judit Bassols 3 , Abel López-Bermejo 4 , Francis de Zegher 5 , Lourdes Ibáñez 1,2 Show Affiliations »
Abstract
Show RCT »
Hide RCT «
CONTEXT: Polycystic ovary syndrome (PCOS ) is a prevalent disorder in adolescent girls, purportedly driven by hepato-visceral fat excess, and often followed by subfertility and type 2 diabetes. OBJECTIVE: We studied the baseline microRNA (miRNA) profile of girls with PCOS , and the effects of a randomized treatment with an oral contraceptive (OC) or with spironolactone-pioglitazone-metformin (SPIOMET, aiming at loss of hepato-visceral fat excess) for 1 year. DESIGN & PATIENTS: The miRNA profile was assessed by RNA sequencing in girls with PCOS who had participated in a randomized, open-label, single-center, pilot study (n = 31; age 15.7 years, body mass index (BMI ) 23.1 kg/m2). Healthy age- and BMI-matched girls (n = 13) served as controls. Differentially expressed miRNAs were validated by RT-qPCR in the entire study population. Post-treatment ovulation rates were assessed by salivary progesterone in PCOS girls. SETTING: Endocrinology Department, University Hospital. RESULTS: Girls with PCOS , compared with controls, had markedly reduced concentrations of circulating miR-451a, miR-652-3p, miR-106b-5p, and miR-206 ; pathway enrichment analysis showed that these miRNAs target genes involved in energy homeostasis and cell cycle control. In the present study, miR-451a could diagnose PCOS with 100% sensitivity and 100% specificity. SPIOMET (but not OC) was accompanied by on-treatment normalization of the miRNA profile in girls with PCOS ; miR-451a concentrations after 1 year on OC or SPIOMET treatment associated closely (r = 0.66; P < .0001) with post-treatment ovulation rates . CONCLUSION: SPIOMET treatment for 1 year normalizes the miRNA profile of girls with PCOS . Circulating miR-451a may become a biomarker to guide the diagnosis and treatment of PCOS in adolescence. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
RCT Entities: Population
Interventions
Outcomes
CONTEXT: Polycystic ovary syndrome (PCOS ) is a prevalent disorder in adolescent girls , purportedly driven by hepato-visceral fat excess, and often followed by subfertility and type 2 diabetes . OBJECTIVE: We studied the baseline microRNA (miRNA) profile of girls with PCOS , and the effects of a randomized treatment with an oral contraceptive (OC) or with spironolactone -pioglitazone -metformin (SPIOMET , aiming at loss of hepato-visceral fat excess) for 1 year. DESIGN & PATIENTS : The miRNA profile was assessed by RNA sequencing in girls with PCOS who had participated in a randomized, open-label, single-center, pilot study (n = 31; age 15.7 years, body mass index (BMI) 23.1 kg/m2). Healthy age- and BMI-matched girls (n = 13) served as controls. Differentially expressed miRNAs were validated by RT-qPCR in the entire study population. Post-treatment ovulation rates were assessed by salivary progesterone in PCOS girls . SETTING: Endocrinology Department, University Hospital. RESULTS: Girls with PCOS , compared with controls, had markedly reduced concentrations of circulating miR-451a , miR-652 -3p, miR-106b-5p, and miR-206 ; pathway enrichment analysis showed that these miRNAs target genes involved in energy homeostasis and cell cycle control. In the present study, miR-451a could diagnose PCOS with 100% sensitivity and 100% specificity. SPIOMET (but not OC) was accompanied by on-treatment normalization of the miRNA profile in girls with PCOS ; miR-451a concentrations after 1 year on OC or SPIOMET treatment associated closely (r = 0.66; P < .0001) with post-treatment ovulation rates. CONCLUSION: SPIOMET treatment for 1 year normalizes the miRNA profile of girls with PCOS . Circulating miR-451a may become a biomarker to guide the diagnosis and treatment of PCOS in adolescence. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Entities: Chemical
Disease
Gene
Species
Keywords:
PCOS; hepato-visceral fat; metformin; miRNAs; pioglitazone; spironolactone
Year: 2020
PMID： 31730174 DOI： 10.1210/clinem/dgz204
Source DB: PubMed Journal: J Clin Endocrinol Metab ISSN： 0021-972X Impact factor: 5.958